{"id":"W4379341627","doi":"10.1200/jco.2023.41.16_suppl.9542","title":"Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nivolumab; Ipilimumab; Internal medicine; Oncology; Progression-free survival; Placebo; Melanoma; Overall survival; Cancer; Immunotherapy; Pathology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007944359,0.000164625,0.0003675479,0.0001346531,0.0001464515,0.0003344912,0.0001810466,0.000274231,0.001767774],"category_scores_gemma":[0.0007531092,0.0001032096,0.0004889957,0.000224831,0.0001820542,0.0002730523,0.0002439742,0.0005155324,0.0001884153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003472072,"about_ca_system_score_gemma":0.0003471479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006145833,"about_ca_topic_score_gemma":0.001191849,"domain_scores_codex":[0.999803,0.00007091117,0.00001394108,0.00003998519,0.00002866128,0.00004353181],"domain_scores_gemma":[0.9994211,0.000126008,0.000242655,0.00002818227,0.00002016422,0.0001618816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2404136,0.004183022,0.6432587,0.0004295834,0.001088852,0.0005700415,0.00022887,0.002350732,0.01932676,0.0001447235,0.002428027,0.08557703],"study_design_scores_gemma":[0.008788875,0.07672418,0.9074757,0.00003436658,0.0006074972,0.0007063383,0.00008715811,0.001427155,0.002061578,0.0001162339,0.001957663,0.0000133441],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989053,0.0003037169,0.00006774165,0.00002789681,0.000005538172,0.00003098858,0.0002882684,0.000004991549,0.0003654854],"genre_scores_gemma":[0.9990923,0.00009123084,0.0000616835,0.00003981975,0.00001065625,0.00003418583,0.0004843212,0.000001017742,0.000184859],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001767774,"threshold_uncertainty_score":0.005913854,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06243232627494016,"score_gpt":0.4151951495386469,"score_spread":0.3527628232637068,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}